Phaseline

Targets › KIT

KIT (Mast/stem cell growth factor receptor Kit): drug programs, companies and trials

52 programs from 40 companies in 298 trials: 178 Phase 2, 76 Phase 1, 39 Phase 3, 5 Phase 4; Oncology, Gastroenterology, Hematology; next expected readout Nov 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. (UniProt, P10721)

Open in Phaseline: the race on KIT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupCatequentinib
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 4Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma …Dec 2026
Blueprint MedicinesAvapritinib (BLU-285)
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 4Mastocytosis, Systemic; Indolent Systemic Mastocytosis; AML (Acute Myelogenous Leukemia); Anatomic Stage IV Breast Cancer AJCC v8 …Jun 2027
Gossamer Bio USASeralutinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor
KIT, PDGFRB, PDGFRA, CSF1RPhase 3Pulmonary Arterial HypertensionDec 2026
Deciphera PharmaceuticalsVimseltinib (DCC-3014)
KIT/PDGFRA/CSF1R inhibitor
CSF1R, KIT, PDGFRAPhase 3Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants …Dec 2026
ExelixisZanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
Xynomic PharmaceuticalsPazopanib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory …Dec 2026
Chia Tai Tianqing Pharmaceutical GroupAL2846 Capsule
Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET
MET, KIT, FLT4, RETPhase 3Thyroid CancerJan 2027
National Cancer Institute (NCI)Pazopanib Hydrochloride
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid NeoplasmFeb 2027
Deciphera PharmaceuticalsRipretinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 3GIST; Gastrointestinal Stromal TumorsMar 2027
Daiichi SankyoPexidartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KITPhase 3Tenosynovial Giant Cell Tumor; Neurofibroma, PlexiformMar 2027
Daiichi SankyoQuizartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KIT, PDGFRB, PDGFRAPhase 3Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult …May 2027
Jiangsu HengRui MedicineFamitinib
Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
KIT, FLT1, FLT3, PDGFRB, PDGFRAPhase 3Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm …May 2027
GSKIDRX-42 (GSK6042981, velzatinib)
Receptor tyrosine kinase inhibitor
KIT, PDGFRAPhase 3Gastrointestinal Neoplasms; Gastrointestinal Stromal NeoplasmsNov 2027
Advenchen LaboratoriesCatequentinib (AL3818)
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 3Alveolar Soft Part SarcomaDec 2027
AB ScienceMasitinib
Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FGFR3, KIT, PDGFRB, PDGFRAPhase 3Amyotrophic Lateral SclerosisDec 2027
Alliance for Clinical Trials in OncologyTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 3Clear Cell Renal Cell CarcinomaNov 2037
RocheSorafenib
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 3Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma …–
Jiangxi Provincial Cancer HospitalAnlotinib hydrochloride
Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT)
VEGFR, FGFR, RET, KITPhase 2Esophageal Squamous Cell CarcinomaNov 2026
M.D. Anderson Cancer CenterSunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate CancerDec 2026
National Cancer Institute (NCI)Sunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine TumorDec 2026
University of UtahXL092 (Zanzalintinib)
Multi-target kinase inhibitor targeting FGFR, VEGFR, and KIT
FGFR, VEGFR, KITPhase 2Metastatic Castration-resistant Prostate CancerDec 2026
Sun Yat-sen UniversityAnlotinib Hydrochloride
Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET
VEGFR, PDGFRA, PDGFRB, FLT1, KITPhase 2GlioblastomaDec 2026
Blueprint MedicinesBLU-808
Wild type KIT inhibitor
KITPhase 2Chronic Inducible UrticariaDec 2026
Canadian Cancer Trials GroupSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Rare TumoursDec 2026
University of MiamiSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsDec 2026
National Cancer Institute (NCI)Imatinib Mesylate
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 2Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure SyndromeMar 2027
National Cancer Institute (NCI)Sorafenib Tosylate
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 2Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid NeoplasmMar 2027
Sarcoma Alliance for Research through CollaborationBezuclastinib
KIT inhibitor
KITPhase 2Gastrointestinal Stromal TumorsJun 2027
Sarcoma Alliance for Research through CollaborationSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsJun 2027
Fudan UniversitySitravatinib
Small molecule inhibitor of receptor tyrosine kinases
PDGFRA, KIT, RET, FLT3Phase 2Metastatic Breast CancerJun 2027
Cogent Biosciencesbezuclastinib
KIT inhibitor
KITPhase 2Advanced Systemic Mastocytosis (AdvSM); SSMJul 2027
American Society of Clinical OncologySunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Lymphoma, Non-HodgkinDec 2027
Bai-Rong XiaSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Ovary CancerDec 2027
Memorial Sloan Kettering Cancer CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2OsteosarcomaMar 2028
BayerRegorafenib (BAY73)
Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor
ABL1, RAF1, KIT, FGFR1, MAPK11Phase 2Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic …Apr 2028
Eye & ENT Hospital of Fudan UniversityAnlotinib Hydrochloride
Multi-target tyrosine kinase inhibitor
VEGFR, FGFR, RET, KITPhase 2Adenoid Cystic CarcinomaJun 2028
National Cancer Institute (NCI)Briquilimab
Stem cell growth factor receptor inhibitor
KITPhase 2GATA2Jul 2028
M.D. Anderson Cancer CenterTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 2Renal Cell CarcinomaNov 2028
NovartisMidostaurin
Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FLT3, KIT, PDGFRB, PDGFRA, PRKD3Phase 2FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid LeukemiaMay 2029
Blueprint MedicinesElenestinib (BLU-263)
KIT inhibitor
KITPhase 2Indolent Systemic MastocytosisSep 2032
Taiho PharmaceuticalImatinib
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 1Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic …Dec 2026
University of FloridaTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1Bile Duct CancerDec 2026
AstraZenecacediranib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
KIT, PDGFRB, PDGFRA, FLT1, FLT4Phase 1Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer …Dec 2026
National Heart, Lung, and Blood Institute (NHLBI)briquilimab
Stem cell growth factor receptor inhibitor
KITPhase 1Sickle Cell Anemia; Sickle Cell DiseaseJan 2027
Etnova TherapeuticsETN101
Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB
FLT3, KIT, VEGFR2, PDGFRBPhase 1Hepatocellular CarcinomaMar 2027
State University of New York at BuffaloSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Carcinoma, Renal CellJul 2027
University of Colorado, DenverSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1OsteosarcomaAug 2027
Novelty NobilityNN3201
anti-c-Kit antibody-drug conjugate with MMAE payload
KITPhase 1Gastrointestinal Stromal TumorsAug 2027
Porteus, Matthew, MDBriquilimab (JSP191)
Stem cell growth factor receptor inhibitor
KITPhase 1Fanconi AnemiaDec 2027
Rabin Medical CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Solid Tumors Refractory to Standard TherapyJan 2028
Ono PharmaceuticalRipretinib (DCC-2618)
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 1Gastrointestinal Stromal TumorsFeb 2028
National Cancer Institute (NCI)Tivozanib (AV-951)
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1CholangiocarcinomaDec 2028

Conditions

Gastrointestinal Stromal Tumors (11) Hepatocellular Carcinoma (10) Acute Myeloid Leukemia (10) Colorectal Cancer (5) Soft Tissue Sarcoma (4) Cervical Cancer (4) Breast Cancer (4) Renal Cell Carcinoma (4) Metastatic Colorectal Cancer (3) Unresectable Hepatocellular Carcinoma (3) Non-Small Cell Lung Cancer (3) Osteosarcoma (3)

Modalities

small molecule (38), mixed (11), antibody (2), other (1)

Companies

National Cancer Institute (NCI) (6) Blueprint Medicines (3) Chia Tai Tianqing Pharmaceutical Group (2) Deciphera Pharmaceuticals (2) Daiichi Sankyo (2) Sarcoma Alliance for Research through Collaboration (2) M.D. Anderson Cancer Center (2) Canadian Cancer Trials Group (1) Novartis (1) Exelixis (1) Ono Pharmaceutical (1) Alliance for Clinical Trials in Oncology (1) Bayer (1) Gossamer Bio USA (1) Fudan University (1) University of Florida (1) Etnova Therapeutics (1) Sun Yat-sen University (1) Memorial Sloan Kettering Cancer Center (1) Advenchen Laboratories (1)

Related targets

PDGFRB (29) PDGFRA (25) FLT3 (19) CSF1R (17) FLT4 (8) FLT1 (7) KDR (6) FGFR1 (4) FGFR3 (4) RET (4) VEGFR (4) RAF1 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.